Thyreogen

ExperimentalKhavinson peptide bioregulator / researchExperimental

Thyreogen is a khavinson peptide bioregulator. The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.

Calculate Dose

For research use only.

Key Facts

CAS
โ€”
Molecular Weight (MW)
โ€”
Half-life
โ€”
FDA status
Not Approved
Administration Route
oral
Frequency
โ€”
Last updated
Aug 30, 2026
Reviewed
Aug 30, 2026

Research summary

Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No controlled human efficacy trials of this specific preparation have been published; the available literature is class-level work on short peptide bioregulators.

Peptide Library's Thyreogen profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Protocol

Dosage Range
โ€”
Frequency
โ€”
Cycle
โ€”
Administration Route
oral
Reconstitution Guide
โ€”

Science

Mechanism of Action

The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials. Claims specific to the thyroid preparation should be read as marketing rather than established pharmacology.

Regulatory & research status

Thyreogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Thyreogen
FDA statusNot Approved
Research statusResearch-only compound; no approval pathway listed
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

Benefits

โ€”

Potential Side Effects

No side effects listed yet for this entry.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freezeโ€“thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution โ†’

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544โ€“575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

Thyreogen: frequently asked questions

What is Thyreogen?

Peptide preparation derived from thyroid tissue and marketed as a tissue-specific bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No controlled human efficacy trials of this specific preparation have been published; the available literature is class-level work on short peptide bioregulators.

How does Thyreogen work?

The Khavinson bioregulator hypothesis holds that short peptides extracted from a given tissue act preferentially on that same tissue, with proposed effects on gene expression and protein synthesis. Most supporting work comes from a single research group, is published largely in Russian-language journals, and has not been independently replicated in controlled human trials.

Is Thyreogen FDA approved?

No. Thyreogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to Thyreogen?

Compounds most often compared with Thyreogen include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial ยท Reviewed Aug 30, 2026 ยท Updated Aug 30, 2026 ยท Version 1

This Thyreogen profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy ยท How profiles are compiled ยท Report an error

Track Thyreogen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android โ†’